Quickly
Socially
Trending
Crypto
Bharat Biotech on March 3 said that results of its Phase 3 clinical trials had shown that the interim clinical efficacy of ‘Covaxin’ is 81 per cent. The vaccine demonstrated 81 per cent interim efficacy “in preventing COVID-19 in those without prior infection after the second dose," the company said. Participants in the phase 3 trials were between 18-98 years of age, including 2,433 over the age of 60 & 4,500 with comorbidities, the company further said. Indian Council of Medical Research (ICMR), which backed the vaccine & jointly conducted the trials, said that the results had been evaluated by an independent data safety & monitoring board. Covaxin is one of the two vaccines against COVID-19, which had been given a green signal by the government for emergency use. However, the approval to the vaccine while it was still in clinical trials, having completed two of the required three rounds, had caused much controversy. Watch the video to know more.
Google Trends
